We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

80 hedge funds and large institutions have $308M invested in Xenon Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

1% more funds holding

Funds holding: 79 → 80 (+1)

0.16% less ownership

Funds ownership: 79.95% → 79.79% (-0.16%)

12% less capital invested

Capital invested by funds: $351M → $308M (-$42.7M)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
80
Holders Change
+1
Holders Change %
+1.27%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
16
Reduced
27
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.01M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$5M
3
SCM
Soleus Capital Management
Connecticut
+$2.93M
4
GIM
Granahan Investment Management
Massachusetts
+$561K
5
Goldman Sachs
Goldman Sachs
New York
+$385K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$2.56M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.5M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.55M
4
PHP
Parkman Healthcare Partners
Connecticut
-$1.48M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
51
Virtus ETF Advisers
New York
$284K -$41.1K -3,497 -12%
NSEDCP
52
NJ State Employees Deferred Compensation Plan
New Jersey
$277K – – –
MWNA
53
Marshall Wace North America
New York
$272K -$76.2K -6,475 -21%
AC
54
Athanor Capital
New York
$272K -$16.5K -1,401 -5%
EWM
55
Elmwood Wealth Management
California
$235K – – –
Geode Capital Management
56
Geode Capital Management
Massachusetts
$213K – – –
PP
57
PDT Partners
New York
$195K -$142K -12,046 -41%
CS
58
Credit Suisse
Switzerland
$151K – – –
QSS
59
Quantitative Systematic Strategies
Florida
$132K +$3.27K +278 +2%
SACTSONJ
60
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$122K – – –
IVM
61
InterWest Venture Management
California
$92K – – –
CSS
62
Cubist Systematic Strategies
Connecticut
$64K -$113K -9,590 -62%
Bank of Montreal
63
Bank of Montreal
Ontario, Canada
$59K – – –
Bank of America
64
Bank of America
North Carolina
$37K -$2.2K -187 -5%
Morgan Stanley
65
Morgan Stanley
New York
$27K -$471 -40 -2%
Canada Life
66
Canada Life
Manitoba, Canada
$27K – – –
UBS Group
67
UBS Group
Switzerland
$22K -$3.39K -288 -13%
CFGS
68
Concourse Financial Group Securities
Alabama
$22K – – –
Legal & General Group
69
Legal & General Group
United Kingdom
$13K – – –
IA
70
IFP Advisors
Florida
$11K – – –
Macquarie Group
71
Macquarie Group
Australia
$9K – – –
Osaic Holdings
72
Osaic Holdings
Arizona
$8K – – –
TRCT
73
Tower Research Capital (TRC)
New York
$8K +$8.38K +712 New
CG
74
Cutler Group
California
$8K +$9.41K +800 New
Lazard Asset Management
75
Lazard Asset Management
New York
$7K +$8.29K +705 New
1 2
3
4

XENE Hedge Fund Activity: Q3 2020 in Review

80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2020, worth a combined $308M — down 12% from $351M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $5.01M. The largest seller was Acuta Capital Partners, cutting an estimated $2.56M.

  • 80 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2020, up from 79 in Q2 2020.
  • Funds reported $308M of Xenon Pharmaceuticals stock for Q3 2020, down 12% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q3 2020 was Fidelity Investments, an estimated $5.01M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2020 was Acuta Capital Partners, an estimated $2.56M sold.

Based on aggregated 13F filings for Q3 2020.